Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults
Sponsor: Regeneron Pharmaceuticals
Summary
This clinical research trial will evaluate the safety and tolerability of an experimental drug, ALN-F1202, in healthy participants. The purpose of this trial is to learn about how safe and tolerable the experimental drug is. The trial is looking at several other research questions, including: * What side effects may happen from taking the experimental drug? * How much experimental drug is in the blood at different times? * Whether the body makes antibodies against the experimental drug (which could make the drug less effective or could lead to side effects). * What is the best dose of the experimental drug?
Official title: A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ALN-F1202, an siRNA Against Factor XII, in Healthy Adults
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
56
Start Date
2025-03-06
Completion Date
2026-07-30
Last Updated
2026-02-23
Healthy Volunteers
Yes
Conditions
Interventions
ALN-F1202
Administered per the protocol
Matching Placebo
Administered per the protocol
Locations (1)
Center for Clinical Pharmacology University Hospitals Leuven (UZ Leuven)
Leuven, Vlaams-Brabant, Belgium